Ablynx N.V.

Belgique


Commandez votre montre hebdomadaire Ablynx N.V.
Quantité totale PI 402
Rang # Quantité totale PI 3 289
Note d'activité PI 3/5.0    138
Rang # Activité PI 4 875
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

182 0
55 5
160 0
0
 
Dernier brevet 2025 - Immunoglobulin variable domains
Premier brevet 2001 - Oral delivery of polypeptides
Dernière marque 2016 - CABLIVI
Première marque 2005 - ABLYNX

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 Invention Polypeptides antagonizing wnt signaling in tumor cells. The invention provides novel LRP5-bindin...
2024 Invention Protein-based carriers for site-specific amine conjugation. The present technology relates to th...
Invention Protein-based carriers for site-specific amine conjugation. The present technology relates to the...
Invention Immunoglobulin single variable domains targeting ceacam5. The present technology provides polypep...
Invention Protein-based conjugation carriers for intranuclear delivery. DD value greater than 5x10-4 mol/li...
Invention Adamts binding immunoglobulins. The present invention relates to immunoglobulins that bind ADAMT...
Invention Glycoengineered fc variant polypeptides with enhanced effector function. The present disclosure ...
Invention Precision activated polypeptides. The present technology provides polypeptides comprising a firs...
Invention Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moi...
Invention Fc domain variants with enhanced fc receptor binding. The present disclosure provides Fc domain ...
Invention Fc domain variants with enhanced fc receptor binding. The present disclosure provides Fc domain v...
Invention Mmp13 binding immunoglobulins. The present invention relates to immunoglobulins that specificall...
Invention Bi- and multivalent albumin binders. The present technology relates to bi- and multivalent albumi...
Invention Method for the production of domain antibodies. The present invention relates to a method for pr...
Invention Fcrn antagonists for treatment of igg-related diseases and disorders. The present invention rela...
Invention Improved fcrn antagonists for treatment of igg-related diseases and disorders. The present invent...
Invention Immunoglobulin single variable domains targeting pd-l1. The present technology provides polypepti...
Invention Chimeric proteins for modulating cytokine receptor activity. The present invention belongs to the...
Invention Polypeptides binding to the neonatal fc receptor. The present technology relates to polypeptides...
Invention Polypeptides binding to the neonatal fc receptor. The present technology relates to polypeptides ...
Invention Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell re...
Invention Serum albumin binders. The present invention relates to amino acid sequences that can bind to se...
2023 Invention Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf alpha. The...
Invention Protein-based conjugation carriers. The present technology relates to the field of drug delivery...
Invention Protein-based conjugation carriers. DD value greater than 5x10-4 mol/litre.
Invention Amino acid sequences that modulate the interaction between cells of the immune system. The prese...
Invention Glycoengineered fc variant polypeptides with enhanced effector function. The present disclosure p...
Invention T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta. Polypeptides are pro...
Invention Polypeptides binding adamts5, mmp13 and aggrecan. The present invention relates to polypeptides ...
Invention Polypeptides binding to a specific epitope of the neonatal fc receptor. The present invention re...
Invention Polypeptides binding to a specific epitope of the neonatal fc receptor. in vivoin vivo of therape...
Invention Cx3cr1-binding compounds, uses thereof and related methods. The present technology relates to a p...
Invention Immunoglobulin single variable domains targeting t cell receptor. The present technology provides...
2022 Invention Aggrecan binding immunoglobulins. The present invention relates to immunoglobulins that specific...
Invention Polypeptides comprising immunoglobulin single variable domains targeting tcrαβ, cd33 and cd123. T...
Invention Immunoglobulin variable domains. VH domain, in which: (i) the amino acid residue at position 112 ...
Invention Obtaining sequence information for target multivalent immunoglobulin single variable domains. A c...
Invention Cysteine linked nanobody dimers. The present invention relates to dimers comprising a first polyp...
Invention Nucleic acids encoding cx3cr1-binding polypeptides comprising immunoglobulin single variable doma...
Invention Nanobodies against tumor necrosis factor-alpha. The present invention relates to improved Nanobo...
Invention Polypeptides comprising immunoglobulin single variable domains targeting tnfa and il-23. The pre...
Invention Glycosylated immunoglobulin single variable domains. The present invention relates to glycosylat...
Invention Adamts binding immunoglobulins. The present invention relates to immunoglobulins that bind ADAMTS...
2021 Invention Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-α. The pres...
Invention Bispecific nanobodies. The present disclosure relates to bispecific polypeptides comprising a fi...
Invention Methods for inhibiting tumor growth or treating cancer by administering an immunoglobulin single ...
Invention Polypeptides antagonizing wnt signaling in tumor cells. The invention provides LRP5-binding polyp...
Invention Method for the production and purification of multivalent immunoglobulin single variable domains....
2016 P/S Pharmaceutical preparations for the prevention and treatment of auto immune disorders, disorders ...
P/S Pharmaceutical preparations and substances for the treatment of pain, viral diseases, namely herp...
2005 P/S Pharmaceutical and veterinary products for the treatment of viral diseases, namely, acquired immu...
P/S Pharmaceutical products for the treatment of viral diseases, namely, acquired immune deficiency s...